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Abstract: 
Objective: Aim of this study was to compare cerebrospinal fluid (CSF) virological 
control, biomarkers and neurocognition of neurologically symptomatic patients on dual 
antiretroviral therapies (DT) versus 2NRTIs-based three-drug regimens (TT). 
Design: Retrospective monocentric cross-sectional study. 
Methods: We analysed data from people living with HIV (PLWH) undergoing lumbar 
puncture for clinical/research reasons with plasma HIV-RNA <200 cp/mL and 
neurological/neurocognitive symptoms without significant contributing comorbidities. 
We measured CSF HIV-RNA, inflammation, blood-brain barrier integrity, neuronal 
damage and astrocytosis biomarkers (5 biomarkers by ELISA and 5 indices by 
immunoturbidimetry) and recorded the neurocognitive performance (14 tests). CSF 
escape was defined as any case of CSF HIV-RNA 0.5 Log10 higher than viremia or any 
case of detectable CSF HIV-RNA coupled with undetectable viremia. 
Results: 78 patients on TT and 19 on DT were included. Overall, 75.3% male, median 
age 51 years (46-58), current CD4 count 545 cells/mmc (349-735), time on current 
regimens 18 months (8-29), but length of plasma suppression 32 months (14-94). The 
two groups did not differ in terms of HIV-associated neurological diagnoses, 
demographic and viro-immunological features. Undetectable CSF HIV-RNA (73.7% in 
DT vs 78.2% in TT, p.67) and CSF escape (21.1% in DT vs. 19.2% in TT, p.86) did not 
differ. No difference was observed in depression, anxiety, neurocognition (in 63 
participants) nor in any tested biomarker. 
Conclusions: In PLWH with neurological/neurocognitive symptoms, peripherally 
effective DT can show CSF viro-suppression, inflammation, neuronal and astrocyte 
integrity and neurocognition comparable to TT. 
 
Keywords: Dual antiretroviral therapy; HIV; Cerebrospinal fluid; Neurocognitive 
disorders; Viral escape; Biomarkers; Viral suppression. 
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Manuscript: 
In the context of life-long combination antiretroviral therapy (cART) for people living 
with HIV (PLWH), long-term drug toxicities, adherence, costs and drug-drug 
interactions have prompted to look for treatment simplification strategies. Recently, 
specific two-antiretroviral-based regimens (DT) proved to be non-inferior compared to 
three-drugs therapies (TT) in terms of viro-immunological control [1]. Lacking 
experimental data, concerns regarding immune-activation, resistance-associated 
mutations (RAMs) selection and viral escape in anatomical reservoirs, such as lymph-
nodes and central nervous system (CNS) have been raised [1–4]. HIV replication may 
persist in tissues of treated patients presenting undetectable viremia and relates to local 
lower drug exposure as compared to plasma levels [4–7]. This raises the question 
whether switching to DT can further increase the risk of virological escapes and impact 
persistent replicating viral reservoir, leading in turn to higher levels of immune-
activation and inflammation-related comorbidities, including HIV-associated 
neurocognitive disorders (HAND). In this regard, clinical reports alerted about the risk 
of cerebrospinal fluid (CSF) viral escape (CVE) during DT, but this message could have 
been distorted by publication bias and by the DT used, which were not always 
supported by trials results [8,9]. Indeed, providing good adherence, CSF viral 
suppression seems to persist after switching to DT [10]. Among aviremic patients both 
AtLaS-M (Atazanavir and Lamivudine for treatment Simplification-Multicentric study) 
and SALT (Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance 
Therapy) trials have demonstrated that, comparing patients switching to DT to those 
remaining in TT, neurocognitive function is stable and similar up to 144 weeks [11,12]. 
Data from the neurocognitive sub-study of the NEAT001/ANRS143 trial (European 
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AIDS Treatment Network 001/French National Agency for AIDS Research 143) on 
viremic patients starting first-line DRV/r+RAL versus DRV/r+2NRTIs are awaited. 
Limitations of these studies were variably the short-term follow-up [10], the restricted 
neurocognitive battery adopted [12] or the significant loss of patients undergoing the 
neurocognitive evaluation during follow-up [11]. Since HIV-related neuropathogenesis 
may not relate immediately and solely to uncontrolled viral replication within CNS and 
may arise after long periods of low-level tissue replication, other tools such as CSF 
biomarkers may be more accurate in detecting alterations at pre-symptomatic stages not 
yet evident at the neurocognitive assessment. On the other hand, archived RAMs and 
virus evolution in reservoirs during cART coupled with specific pharmacokinetic 
considerations in brain tissues may indicate that a surprising proportion of PLWH on 
TT is actually on mono/dual functional therapies [7,13–15], undermining the 
preconceived superiority of TT over well-tailored DT. Therefore, considering the 
unsolved concerns and the gaps between the ideal world of clinical trials and the reality 
of clinical settings, we have retrospectively analysed data of our Neuro-AIDS cohort 
consisting of more than 500 HIV-positive neurologically/neurocognitively symptomatic 
adult patients undergoing lumbar puncture (LP) for clinical and/or research reasons. 
Specifically, we have compared the virological control within CSF, several biomarkers 
of CNS functions and the neurocognition of patients presenting suppressed or low-level 
viremia (LLV) and no other neurological confounding on DT vs TT based on 2NRTIs 
plus a third drug. Our primary objective was to assess whether DT hold higher risk of 
CSF virological failure in such a clinical setting of high-risk adult patients. Our 
secondary aim was to evaluate whether DT associate with a heavier burden of CSF 
inflammation, CNS injury and/or poorer neurocognition. 
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Methods 
Study design and patients 
We performed a retrospective cross-sectional study nested in ongoing prospective 
studies on HIV-related neurological/neurocognitive disorders (Prospective study on 
predictors of neurocognitive decline in HIV-positive patients PRODIN, Study of nasal 
brushing collected olfactory mucosa samples in the diagnosis of human 
encephalopathies SOLFAMU, and Maraviroc-based treatment switch in HIV-positive 
patients with HAND: consequences of reducing antiretroviral-associated neurotoxicity 
MARANDX study, all approved by the local Ethics Committee). Data collected from 
PLWH undergoing LP for clinical and/or research reasons at our centre (Infectious 
Diseases Clinic, Amedeo di Savoia hospital, Torino) from 2010 to February 2019 were 
retrospectively analysed. Inclusion criteria were as follows: age ≥18 years; being on any 
type of DT or 2NRTIs-based TT; being stably on the same cART regimen since at least 
3 months before LP; plasma HIV-RNA<200 cp/mL since at least 6 continuous months 
before LP. Exclusion criteria were as follows: active/previous CNS infective, 
neoplastic, traumatic, vascular, inflammatory or neurodegenerative disorders; disclosure 
of substance or alcohol abuse within the last year from LP; clinically relevant scores at 
the Beck Depression Inventory-II (≥30) or at the Hamilton Anxiety Rating Scale (≥25).  
Neurocognitive evaluation 
The neurocognitive battery consisted of: Trail Making Test A for processing 
speed/reaction time, Trail Making Test B and Stroop Colour test for executive 
functioning, Digit Span forward, Digit Span backward and Digit Symbol for 
attention/working memory, Corsi test and Disyllabic Words Serial Repetition test for 
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visuo-spatial and verbal short-term memory, Free and Cued Selective Reminding, Story 
Recall and Rey-Osterrieth Complex Figure Delayed Recall tests for verbal long-term 
memory and learning, Phonemic Verbal Fluency for language skills, Grooved Pegboard 
for Dominant/Non-dominant hand test for motor skills and Rey-Osterrieth Complex 
Figure Copy test for visuo-construction ability. Raw scores were converted to age-, sex- 
and education-adjusted normative t-scores in accordance with published manuals. 
HAND diagnosis was performed according to Frascati’s criteria [16]. Daily functioning 
impairment was assessed by the Instrumental Activities of Daily Living. 
Cerebrospinal fluid analysis 
Quantitative determination of intrathecal synthesis and blood-brain barrier (BBB) 
damage markers (CSF-serum albumin ratio CSAR, IgG index, intrathecal synthesis, 
Tourtelotte and Tibbling indices) were measured by immunoturbidimetric methods 
(AU5800, Beckman Coulter, Brea, CA, USA) and calculated by Reibergram, as 
previously described [17]. Reference values: CSAR <6.5 up to 40 years and <8.0 in 
patients aged above; IgG index <0.7; intrathecal synthesis 0%. CSF total tau (t-tau), 
phosphorylated tau (p-tau), β-amyloid1-42 (Aβ1-42), neopterin and S100β were 
measured by immunoenzymatic methods (Fujirebio diagnostics, Malvern, USA; R&D 
Systems Europe, Ltd. Abingdon, UK; DRG Diagnostics, Marburg, Germany; Diametra 
Srl, Spello, Italy). Reference values: t-tau <300 pg/mL in patients aged 21–50, <450 
pg/mL in patients aged 51–70 and <500 pg/mL in older; p-tau <61 pg/mL; Aβ1–42 
>500 pg/mL; neopterin <1.5 ng/mL; S100β <380 pg/mL. HIV-RNA was quantified by 
the Roche Amplicor assay v2.0 (Hoffman-La Roche, Basel, Switzerland) with a lower 
limit of quantification of 20 copies/mL. CNS penetration-effectiveness score (CPE) was 
derived from Letendre et al and updated with approximation on similarities and 
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preliminary data for newer drugs [18]. CVE was defined as any case of CSF HIV-RNA 
0.5 Log10 higher than plasma HIV-RNA or any case of detectable CSF HIV-RNA 
coupled with undetectable plasma HIV-RNA [19]. Any plasma HIV-RNA 
determination between 20 and 200 cp/ml was defined as LLV. 
Statistical analysis 
Data were analysed using standard non-parametric statistical methods considering the 
variables distribution (Mann–Whitney, Chi-squared and Fisher exact tests). Continuous 
variables were described as medians (interquartile ranges) and discrete variables were 
described as absolute number (percentage). The significance threshold to reject the null 
hypothesis was set at 5% (α=0.05, two-tailed predictions). Bonferroni correction was 
applied when appropriate. Data analysis was performed using SPSS software for 
Windows (version 25.0. IBM Corp).  
Results 
Population 
97 patients met our inclusion criteria and were analysed. 19 patients were on DT and 78 
on TT. DT were as follows: 12 INI+boosted PI (63.2%), 3 INI+nNRTI (15.8%), 2 
boosted PI+nNRTI (10.5%) and 2 boosted PI+NRTI (10.5%). 1 started DT as naïve, 
while the others (94.7%) switched from other regimens. Before starting DT, 10 patients 
(52.6%) showed a plasma HIV-RNA<20 cp/mL, being the median plasma HIV-RNA 
among unsuppressed patients 33 cp/mL (22-690). The median time on DT was 20 
months (12-60), while the time spent on previous regimen was 27 months (16-44). 
Demographic and clinical data of the 19 patients on DT are reported in details in 
Supplementary fig.1 http://links.lww.com/QAD/B773. Among TT, 24 patients (30.8%) 
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were on 2NRTIs+boosted PI and 27 (34.6%) on 2NRTIs+INI and 2NRTIs+nNRTI 
both. They were on the current TT since 16 months (7-27) and spent 23 months (15-41) 
on previous regimens (79.5% coming from another TT, 19.2% starting the current TT as 
naïve and 1 from DRV/r+RAL). 
Indications for LP were as follows (the same patient may present more than one): 
neurological signs or symptoms (DT: 12, 63.2%; TT: 50, 64.1%), neurocognitive 
complaints (DT: 8, 42.1%; TT: 36, 46.2%), brain MRI abnormalities (DT: 14, 73.7%; 
TT: 44, 56.4%), other clinical reasons (DT: 1 syphilis and 1 follow-up in previous 
rebound HIV encephalitis, 10.5%; TT: 2 Non Hodgkin lymphoma prophylaxis, 2 
syphilis, 5.1%) and research purposes (DT: 5, 26.3%; TT: 18, 23.1%). No difference 
was observed between DT vs TT at the comparison for LP indications. 
Similarly, after the diagnostic work-up, no significant difference was observed in terms 
of prevalence of diagnosed clinical conditions. Specifically (multiple diagnoses per 
individual were recorded): HAND (for patients who underwent the neurocognitive 
assessment, see below; DT: 10/11, 90.9%; TT: 38/52, 73.1%), CVE (DT: 4, 21.1%; TT: 
15, 19.2%), isolated brain MRI abnormalities (DT: 4, 21.1%; TT: 18, 23.1%) and 
alternative diagnoses excluded (DT: 3, 15.8%; TT: 14, 17.9%). A definitive diagnosis 
among patients complaining of neurocognitive or neurological signs or symptoms was 
reached in similar percentage (9/13, 69.2% in DT vs 34/51, 66.7% in TT; p.86). 
No significant differences in terms of demographic and viro-immunological features 
were observed, as shown in Tab.1. DT showed a trend for a higher proportion of 
patients with a history of LLV and for a smaller proportion presenting plasma HIV-
RNA<20 cp/mL at LP (Tab.1). Furthermore, the groups did not differ in the duration of 
continuous virological suppression, while the length of time from HIV diagnosis was 
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longer for DT but the difference did not reach the significance threshold and none was 
diagnosed during primary HIV infection (Tab.1). 
Cerebrospinal fluid virological suppression 
As shown in Tab.1, despite the expected lower RAMs-unadjusted CPE score in DT, the 
amount of CSF HIV-RNA did not differ between the groups: 14 patients on DT (73.7%) 
presented a CSF HIV-RNA below the detection limit and similarly it was in TT (78.2%; 
Tab.1). Among patients with detectable CSF virus, CSF HIV-RNA was 120 (45-182) 
and 54 cp/mL (43-77) in DT and TT, respectively (p.1.0; Tab.1). Lastly, the prevalence 
of CVE was similar among the groups: 4 cases in DT and 15 among TT (21.1% vs 
19.2%; p.86). 
Neurocognition 
63 patients (64.9%) underwent the neurocognitive assessment: 11 on DT and 52 on TT. 
As shown in Tab.2, the groups did not score differently at the depression and anxiety 
questionnaires. HAND prevalence did not differ between DT and TT (90.9% vs 73.1%; 
p.21), as well as the distribution of HAND grades (Tab.2). Comparing the groups, there 
was no difference in raw or adjusted scores in any neurocognitive tests (data not 
shown). 
Cerebrospinal fluid biomarkers 
Comparing patients on DT vs TT, there was no difference at any tested CSF biomarkers 
of intrathecal humoral response (intrathecal synthesis, IgG index, Tourtelotte and 
Tibbling indices), inflammation and monocyte/macrophages activation (cells, proteins, 
neopterin), BBB integrity (CSAR), astrocytosis (S100β), neuronal injury (tau, p-tau) 
and amyloid metabolism (Aβ1-42), as shown in Tab.2-Fig.1. Since CSAR and CSF tau 
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have different age-adjusted cut-offs of normality, we also assessed the proportion of 
patients with altered CSAR and CSF tau. No significant difference was registered 
between the groups: altered CSF tau levels in 5.9% vs 2.9% of patients on DT and TT, 
respectively (p.55); impaired BBB integrity in 5.6% vs 21.9% of patients on DT and 
TT, respectively (p.11). 
Discussion 
In our cohort of adult PLWH with suppressed or LLV undergoing LP due to 
neurological or neurocognitive issues or neurologically-oriented research purposes, DT 
showed similar efficacy in suppressing viral replication within CSF compared to 
standard TT. 
The study subjects represent a clinical group of patients characterized by a high risk of 
presenting CSF alterations and/or an abundant compartmentalized CNS reservoir, as 
confirmed by the significantly higher prevalence of observed CVE and HAND than 
those recently reported [19–22]. Given this, patients on DT did not show greater 
prevalence of CVE than TT and the amount of quantifiable CSF virus was also similar. 
Since we were not able to calculate for every patient a genotypic susceptibility-adjusted 
CPE score, which seems to better relate to neurocognitive performance and CVE risk 
[23,24], we cannot rule out that the observed equivalence in CSF viro-suppression could 
be partially affected by discrepancies in RAMs between the groups. Among patients 
with available data (37 TT; 11 DT), those on TT presented a lower prevalence of 
cumulative genotype testing positive to RAMs compared to DT (reverse transcriptase 
and protease 37.8% and 31.4% vs 72.7% and 45.4%). Although the available data for 
TT may not be representative for the whole group, we can infer that our patients on TT 
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should have a similar or lower RAMs prevalence than those on DT, reliably reducing 
the risk of a biased non-rejection of the null hypothesis. 
Considering also other acknowledged risk factors for CVE [25,26], DT and TT did not 
differ in terms of CD4 nadir and duration of cART, while the former were 
disadvantaged by a trend to significance of more subjects with a LLV history and of 
longer duration of the infection. Nevertheless, both the groups showed an equivalent 
long-lasting plasma viral suppression, whereby, although these mild unfavourable 
differences against DT in terms of CVE risk, CVE prevalence in DT and in TT 
overlapped. In line with this, also the neurocognitive performance and the alterations in 
all the measured CSF biomarkers were similar between the groups. In contrast to 
clinical trials reporting neurocognitive data, our sample was larger [11] or analysed 
through an extensively wider battery [12] assessing 9 neurocognitive domains. As for 
trials aviremic patients [11,12], compared to patients on TT, those on DT did not 
present a higher prevalence of HAND nor reduced performances in specific tasks that 
may be expected considering recent data on intertwined associations between drug 
classes/molecules, neurocognitive functions and differential penetration in brain areas 
[27,28]. This observation has to be interpreted knowing that HAND development timing 
is not clear and that our neurocognitively tested patients were on DT since a median 
time of almost 4 years but with a large variability within the sample (minimum 4 – 
maximum 124 months).  
Concerning the time of the development of CNS complications, neuropathogenesis may 
not relate immediately and solely to uncontrolled viral replication within CNS and may 
arise after long periods of low-level CSF viremia or even optimal suppression [29,30]. 
In fact, we have analysed CSF cell-free HIV-RNA only, but both cell-associated HIV-
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DNA and HIV-RNA have been detected with a significant higher prevalence compared 
to CSF cell-free HIV-RNA among on cART patients and the presence of the former has 
been associated with worse neurocognitive outcomes regardless of age and nadir CD4 
count prior to the patient's initiation of cART [31]. If available, the assessment of HIV-
DNA and RNA within CSF cells may reveal differences between DT and TT that the 
simple cell-free RNA cannot, especially in cohorts of patients with high prevalence of 
undetectable CSF HIV-RNA, such as ours. 
The absence of any difference in CSF biomarkers of intrathecal humoral response, 
inflammation, monocyte/macrophages activation, BBB integrity, astrocytosis, neuronal 
injury and amyloid plaques deposition, already variably associated with viral 
replication, CVE and with the presence and severity of HAND [26,32–35], once again 
confirms the equality in safety and effectiveness of DT and TT in our clinical setting.  
Interestingly, some of the pathways linked to the CSF biomarkers used here have also 
been associated to cART-related neurotoxicity [36–38]. The lack of any difference in 
CSF biomarkers in an era where one of the main driver to DT simplification is the pro-
active prevention of cART-related toxicity could be disappointing. This conclusion has 
to be confirmed by larger samples, longer observational periods, alternative biomarkers 
and analyses and should consider possible legacy effects of previous regimens and 
treatment holidays as well as the ARVs molecules included/excluded from DT. For 
instance, we found that patients on TT have BBB alterations four times more commonly 
than those on DT. Despite the difference was not statistically significant, the finding 
requires further studies since evidence exists on BBB injury caused by some ARVs, 
primarily EFV [37,39], which is not included in any current DT. 
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Lastly, from a clinical point of view, neurological and neurocognitive issues of patients 
on DT were similar to those registered among TT, as well as for the results of the 
diagnostic work-up. Furthermore, among patients complaining of signs or symptoms, a 
final conclusive diagnosis was reached in identical proportions. Despite preliminary, 
this observation may also suggest that CNS complications and challenges in clinical 
management may not be affected by being on a DT instead of a TT. 
The subsequent follow-up of the patients allowed us to exclude those with neurological 
conditions unclear at LP but already likely present biasing CSF analysis. Thus, despite 
retrospective, clinical confounders were limited. 
Only 1 included DT can be considered as a modern DT (DTG-based) and, overall, only 
7 (36.8%) are currently recommended by guidelines (DTG+RPV; RAL+boosted DRV). 
Therefore, our DT sample is mostly represented by PI-based or old unconventional non-
PI-based DT, presenting possible representativeness issues that require a confirmation 
in larger samples of modern DT. Considering our sample size and inclusion criteria and 
the fact that the majority of patients on DT switched from TT, further studies on larger 
samples of neurologically and neurocognitively asymptomatic PLWH including naïve 
starting on DT are also warranted to assess our findings in different clinical settings.  
Several reasons can explain the observed equality between DT and TT in terms of CNS 
efficacy and safety. Firstly, it is the result of balancing direct and indirect viral 
neurotoxicity with cART-related direct and indirect neurotoxicity. Secondly, taking into 
account ARVs differential and molecule-specific penetration across BBB, their 
diffusion and concentration through the several brain areas and cells and their 
differential intracellular inhibitory potential within the cells types (macrophages/glial 
cells versus neurons versus astrocytes), as well as possible archived RAMs and the 
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established CNS reservoir with its dynamics of decay and evolution under cART [7,13–
15,27,40], the residual activity of some TT (actually functional dual therapies) may 
overlap the one of well-patient-tailored DT, but with an addition of toxicity. Lastly, an 
effective long-lasting and continuous virological suppression in blood, characterising 
both the groups, may be enough to restore an efficient immune system and this, in turn, 
may be sufficient for an adequate CNS functioning [12,41]. 
In conclusion, our retrospective analysis on a small but highly characterized sample 
suggests that, among symptomatic patients with peripheral virological control, DT can 
be as effective and safe as TT within the CNS compartment. Further studies on larger 
samples, different clinical conditions and with long-term prospective design are 
warranted to confirm that the removal of a drug over three of a standard regimen might 
not make the difference within CNS in patients with durable virological suppression in 
blood.  
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Figure: 
 
Figure 1. Comparison of representative cerebrospinal fluid biomarkers in patients 
on dual versus 2NRTI-based three-drug regimens 
The median CSF concentrations of CSF-serum albumin ratio, neopterin and total tau 
protein (top left, middle and right corner, respectively) did not significantly differ 
between DT and TT, as well as the median CSF concentrations of Amyloid β 1-42 
fragment, IgG index and S100β protein (lower left, middle and right corner, 
respectively). Data were analysed by Mann-Whitney test. Legend: DT Dual therapies; 
TT 2NRTI-based three-drug therapies; CSF Cerebrospinal fluid; IgG Immunoglobulin 
G. 
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Tables: 
Table 1. Demographic and viro-immunological characteristics of individuals on 
dual regimens versus 2NRTIs-based three-drug regimens 
Parameter DT (19) TT (78) p 
Male, n 14 (73.7%) 59 (75.6%) .86 
Age, years 57 (51-60) 50 (45-56) .11 
Caucasian, n 18 (94.7%) 74 (94.9%) .98 













HCV coinfection, n 7 (36.8%) 28 (35.9%) .94 
Time from HIV diagnosis, months 242 (177-316) 162 (67-227) .092 
Time on current cART, months 20 (12-60) 16 (7-27) .57 
Continuous virological suppression, months 59 (24-87) 31 (14-95) .28 
Current CD4 count, cell/mmc 626 (375-919) 541 (338-734) .96 
CD4/CD8 ratio 0.7 (0.4-1.0) 0.8 (0.5-1.2) .71 
CD4 count nadir, cell/mmc 99 (35-256) 190 (70-284) .64 
CD4 count nadir<200 cell/mmc, n 11 (57.9%) 41 (52.6%) .68 
Plasma HIV-RNA <20 cp/mL, n 15 (78.9%) 72 (92.3%) .088 
Plasma HIV-RNA, Log10 cp/mL° 2.0 (1.8-2.1) 1.5 (1.5-1.7) .52 
History of LLV, n 3 (15.8%) 3 (3.8%) .054 
CPE score 6 (5-6) 7 (6-8) .020 
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CSF HIV-RNA<20 cp/mL, n 14 (73.7%) 61 (78.2%) .67 
CSF HIV-RNA, Log10 cp/mL* 2.1 (1.6-2.3) 1.7 (1.6-1.9) 1.0 
 
°Among patients with detectable plasma HIV-RNA at lumbar puncture time. *Among 
patients with detectable CSF HIV-RNA. Mann–Whitney test and Chi-squared test were 
used for continuous and discrete variables, respectively. Legend: DT Dual therapies; TT 
2NRTI-based three-drug therapies; MSM Males who have sex with other males; IDU 
Intravenous drug users; cART Combination antiretroviral therapy; LLV Low-level 
viremia; CPE Central Nervous System Penetration and Effectiveness; CSF 
Cerebrospinal fluid. 
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Table 2. Neurocognitive performance and cerebrospinal fluid biomarkers levels in 
patients on dual regimens versus 2 NRTIs-based three-drug regimens 
Parameter DT (11) TT (52) p 
Neurocognition 
Education, years 8 (8-13) 8 (8-13) .81 
BDI-II score 4 (1-9) 6 (2-17) .54 

















Parameter DT (19) TT (78) p 
Intrathecal Synthesis and CSF Humoral response 
Tourtelotte index 0.55 (0-7.55) 0 (0-8.9) .75 
Tibbling index 0.60 (0.48-0.92) 0.60 (0.40-0.80) .91 
IgG index 0.31 (0.26-0.49) 0.36 (0.23-0.52) .60 
Intrathecal synthesis, % 0 (0-31) 0 (0-0) .61 
CSF Inflammation and Immune-activation 
CSF cells, cell/ml 0 (0-2) 0 (0-0) .29 
CSF proteins, mg/ml 43 (35-55) 48 (38-60) .51 
CSF neopterin, ng/ml 0.77 (0.56-1.2) 0.79 (0.34-1.4) .82 
Blood-brain barrier integrity & cell-line specific CSF biomarkers 
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CSF-Serum Albumin ratio 4.9 (3.7-7.1) 5.9 (4.2-7.8) .29 
CSF tau, pg/ml 135 (38-248) 153 (86-242) .59 
CSF phospho-tau, pg/ml 29 (22-44) 35 (28-48) 1.0 
CSF Aβ 1-42, pg/ml 919 (671-1002) 938 (700-1100) .96 
CSF S100β, pg/ml 109 (62-241) 130 (83-186) .60 
 
Mann–Whitney test and Chi-squared test were used for continuous and discrete 
variables, respectively. Legend: DT Dual therapies; TT 2NRTI-based three-drug 
therapies; BDI-II Beck Depression Inventory II; HARS Hamilton Anxiety Rating scale; 
HAND HIV-Associated Neurocognitive Disorders; ANI Asymptomatic Neurocognitive 
Impairment; MND Mild Neurocognitive Disorders; HAD HIV-Associated Dementia; 
CSF Cerebrospinal fluid; IgG Immunoglobulin G; Aβ 1-42 Amyloid β 1-42 fragment. 
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